D1EX34.SA
DexCom, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "6db93904-9bca-4fb8-9fe2-7852e973a6fe",
"title": "Insider Sale: EVP Strategy and Corporate Development Matthew Dolan Sells Shares of DexCom Inc (DXCM)",
"description": "Matthew Dolan, Executive Vice President of Strategy and Corporate Development at DexCom Inc (DXCM), sold 2,423 shares of the company on May 15, 2024. The t",
"keywords": "GuruFocus, Article, News, GuruFocus Research, DXCM",
"snippet": "Matthew Dolan, Executive Vice President of Strategy and Corporate Development at DexCom Inc (DXCM, Financial), sold 2,423 shares of the company on May 15, 2024....",
"url": "https://www.gurufocus.com/news/2440377/insider-sale-evp-strategy-and-corporate-development-matthew-dolan-sells-shares-of-dexcom-inc-dxcm",
"image_url": "https://static.gurufocus.com/logos/0C00000AXT.png?13",
"language": "en",
"published_at": "2024-05-16T23:00:38.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "D1EX34.SA",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 75.22684,
"sentiment_score": 0.48295,
"highlights": [
{
"highlight": "Matthew Dolan, Executive Vice President of Strategy and Corporate Development at <em>DexCom</em> <em>Inc</em> (DXCM, Financial), sold 2,423 shares of the company on May 15, 2024. The transaction was reported in a recent SEC Filing. Following this transaction, the insider has sold a total of 15,382 shares over the past year, with no recorded purchases.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>DexCom</em> <em>Inc</em> (DXCM, Financial) specializes in the development, manufacturing, and distribution of continuous glucose monitoring systems for diabetes management. The technology aims to simplify and improve life for people with diabetes by providing real-time glucose readings, data trends, and alerts to help maintain balanced glucose levels.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "On the date of the sale, shares of <em>DexCom</em> <em>Inc</em> were priced at $126.58. This valuation places the market cap of the company at approximately $52.46 billion. The price-earnings ratio of the stock stands at 85.10, which is above the industry median of 29.3.",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "According to the GF Value, the intrinsic value of <em>DexCom</em> <em>Inc</em> is estimated at $154.82 per share, making the stock modestly undervalued with a price-to-GF-Value ratio of 0.82.\n\nThe insider transaction history for <em>DexCom</em> <em>Inc</em> shows a trend of more sales than purchases among insiders over the past year, with 47 insider sales and no insider buys.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "This sale by the insider might be of interest to current and potential investors, providing insight into insider confidence and valuation perspectives at <em>DexCom</em> <em>Inc</em>.\n\nThis article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Insider Sale: EVP Strategy and Corporate Development Matthew Dolan Sells Shares of <em>DexCom</em> <em>Inc</em> (DXCM)",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "8d6ff84f-b226-4fe7-9456-b9b55bc149e6",
"title": "Phenomix Sciences Announces $5.5M Series A",
"description": "MENLO PARK, CA, Phenomix Sciences has secured $5.5 million in Series A funding.",
"keywords": "",
"snippet": "Phenomix Sciences Announces $5.5M Series A Back to Home\n\nMENLO PARK, CA, Phenomix Sciences has secured $5.5 million in Series A funding.\n\nPhenomix Sciences, a p...",
"url": "https://vcnewsdaily.com/phenomix-sciences/venture-capital-funding/yykkvsjkcs",
"image_url": "https://vcnewsdaily.com/images/vcnd-logo.png",
"language": "en",
"published_at": "2024-05-16T17:53:03.000000Z",
"source": "vcnewsdaily.com",
"relevance_score": null,
"entities": [
{
"symbol": "D1EX34.SA",
"name": "DexCom, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.771286,
"sentiment_score": 0.7003,
"highlights": [
{
"highlight": "Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, <em>DexCom</em>, <em>Inc</em>. and Labcorp, and existing investors, including Health2047.",
"sentiment": 0.7003,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "D1EX34.SA",
"total_documents": 2,
"sentiment_avg": 0.591624990105629
}
]
}
Other details
Exchange
- The B3 S.A. - Brasil, Bolsa, Balcão
- equity
- Healthcare
- br